NOVATO, CA, Amlogenyx Inc. has completed a seed funding round of $14 million.
GordonMD Global Investments LP announced that Amlogenyx Inc. has completed a seed funding round of USD 14 million. Amlogenyx, a subsidiary of Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE), is researching and developing novel gene therapies for Alzheimer's disease and other amyloid diseases.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
